Addyi FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved August 18, 2015)
Brand name: Addyi
Generic name: flibanserin
Dosage form: Tablets
Company: Sprout Pharmaceuticals, Inc.
Treatment for: Hypoactive Sexual Desire Disorder
Addyi (flibanserin) is a non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of hypoactive sexual desire disorder in premenopausal women.
Development timeline for Addyi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.